antiretrovirals

Question 1

standard ART

Answer 1

2 NRTIs + 1 active agent from another class (triple therapy)

Question 2

fovir, vudine, cavir class

Answer 2

NRTIs

Question 3

NRTIs for HBV

Answer 3

tenofovir, emtricitabine, lamivudine

Question 4

NRTI eliminations

Answer 4

renally (except abacavir)

Question 5

navir class

Answer 5

NNRTIs

Question 6

NNRTIs ADEs

Answer 6

hepatotoxicity, rash

Question 7

DDI more common in NRTI vs NNRTI

Answer 7

NNRTI

Question 8

NNRTIs DDI

Answer 8

CYP3A4, acid suppressants (rilpivirine)

Question 9

navir class

Answer 9

protease inhibitor

Question 10

navir ADEs

Answer 10

increased GI + metabolic toxicity

Question 11

navir 3A4 inhibition causes

Answer 11

increased bioavailability, decreased risk of resistance

Question 12

tegravir class

Answer 12

INSTI

Question 13

INSTI ADEs

Answer 13

well-tolerated

Question 14

elvitegravir requirement

Answer 14

booster (COBI)

Question 15

entry inhibitors

Answer 15

maraviroc, ibalizumab, fostemsavir

Question 16

maraviroc, ibalizumab, fostemsavir use

Answer 16

multi-drug resistance

Question 17

maraviroc needs

Answer 17

trophile test

Question 18

TDF vs TAF tox.

Answer 18

TDF more bone + renal tox.

Question 19

NNRTI resistance

Answer 19

lowest barrier to resistance

Question 20

abacavir requirements

Answer 20

test